ACLY inhibitors induce apoptosis and potentiate cytotoxic effects of sorafenib in thyroid cancer cells.

PURPOSE: ATP-citrate lyase (ACLY) is a critical enzyme at the intersection of glucose and lipid metabolism. ACLY is often upregulated or activated in cancer cells to accelerate lipid synthesis and promote tumor progression. In this study, we aimed to explore the possibility of utilizing ACLY inhibition as a new strategy in the treatment of thyroid cancer. METHODS: Bioinformatics analysis of the public datasets was performed. Thyroid cancer cells were treated with two different ACLY inhibitors, SB-204990 and NDI-091143. RESULTS: Bioinformatics analysis revealed that ACLY expression was increased in anaplastic thyroid cancer. In thyroid cancer cell lines FTC-133 and 8505C, ACLY inhibitors suppressed monolayer cell growth and clonogenic ability in a dose-dependent and time-dependent manner. Flow cytometry analysis showed that ACLY inhibitors increased the proportion of sub-G1 cells in the cell cycle and the number of annexin V-positive cells. Immunoblotting confirmed caspase-3 activation and PARP1 cleavage following treatment with ACLY inhibitors. Compromised cell viability could be partially rescued by co-treatment with the pan-caspase inhibitor Z-VAD-FMK. Additionally, we showed that ACLY inhibitors impeded three-dimensional growth and cell invasion in thyroid cancer cells. Isobolograms and combination index analysis indicated that ACLY inhibitors synergistically potentiated the cytotoxicity rendered by sorafenib. CONCLUSIONS: Targeting ACLY holds the potential for being a novel therapeutic strategy for thyroid cancer.

Venous outflow reconstruction using an expanded polytetrafluoroethylene vascular graft in living-donor liver transplant: a single-center experience.

OBJECTIVES: Limited studies have focused on the feasibility and technical requirements of using expanded polytetrafluoroethylene vessel grafts for venous outflow reconstruction in a living-donor liver transplant using right liver grafts without the middle hepatic vein. MATERIALS AND METHODS: Between August 2007 and December 2012, thirty-two patients who had received an expanded polytetrafluoroethylene vascular graft for outflow reconstruction during a living-donor liver transplant using a right liver graft without the middle hepatic vein were retrospectively reviewed. Preoperative and operative data, complications, and mortality were compared among patients who received the expanded polytetrafluoroethylene grafts with individual anastomoses (n = 18) or confluent anastomoses (n =14). RESULTS: For patients who had received an individual and a confluent anastomosis, graft reconstruction time was 25.8 and 14.9 minutes (P = .000). No cases of graft occlusion occurred during first 72 hours after surgery. Although 5 patients (15.6%) died within 90 days, none of the deaths were associated with the vascular grafts. Operative mortality was not statistically different between patients who had received an individual anastomosis (3/18, 16.7%) and those who had received a confluent anastomosis (2/14, 14.3%) (P = 1.000). CONCLUSIONS: Individual and confluent anastomoses using an expanded polytetrafluoroethylene vascular graft is a feasible approach to venous outflow reconstruction in a living-donor liver transplant using right liver grafts without the middle hepatic vein.